Leukemia research最新文献_第2页

Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: Insights from a single center 噻替帕-布磺安-氟达拉滨调理法是治疗髓外受累血液恶性肿瘤的单倍体同种异体造血干细胞移植前的有效方法：来自单一中心的启示。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-11-07 DOI: 10.1016/j.leukres.2024.107617

Xianbo Huang , Xianhui Wu , Shasha Wang , Yanling Ren , Yu Xu , Chen Mei , Jie Jin , Hongyan Tong , Jiejing Qian

引用次数: 0

Causes of death in patients with myelodysplastic syndrome and spliceosome mutations 骨髓增生异常综合征和剪接体突变患者的死亡原因。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-11-06 DOI: 10.1016/j.leukres.2024.107612

Panayiotis D. Kontoyiannis , Arjun S. Peddireddy , Koji Sasaki, Kelly Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos Bueso-Ramos, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

引用次数: 0

Advances in the treatment of mantle cell lymphoma with BTK inhibitors 用 BTK 抑制剂治疗套细胞淋巴瘤的进展。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-11-05 DOI: 10.1016/j.leukres.2024.107615

Jiwei Shen , Jiawei Li , Rui Yang , Shuang Wu , Zhimei Mu , Shi Ding , Xinyu Zhang , Meiying Duo , Ye Chen , Ju Liu

{"title":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","authors":"Jiwei Shen , Jiawei Li , Rui Yang , Shuang Wu , Zhimei Mu , Shi Ding , Xinyu Zhang , Meiying Duo , Ye Chen , Ju Liu","doi":"10.1016/j.leukres.2024.107615","DOIUrl":"10.1016/j.leukres.2024.107615","url":null,"abstract":"<div><div>Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107615"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population 类固醇难治性急性/慢性移植物抗宿主疾病的治疗：在高风险人群中使用鲁索利替尼联合体外射频消融术的单中心实际经验

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-29 DOI: 10.1016/j.leukres.2024.107611

V. Wais, A. Gantner, K. Strauss, A. Neagoie, C. Weidt, J. Schnell, H. Döhner, D. Bunjes, E. Sala

{"title":"Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population","authors":"V. Wais, A. Gantner, K. Strauss, A. Neagoie, C. Weidt, J. Schnell, H. Döhner, D. Bunjes, E. Sala","doi":"10.1016/j.leukres.2024.107611","DOIUrl":"10.1016/j.leukres.2024.107611","url":null,"abstract":"<div><div>Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107611"},"PeriodicalIF":2.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review 皮肤黑色素瘤与血液系统恶性肿瘤并发的流行病学和遗传学研究：荟萃分析综述。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-26 DOI: 10.1016/j.leukres.2024.107610

Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107610"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology 利用微细胞技术对原发性多发性骨髓瘤细胞的药物反应进行体外测试

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-26 DOI: 10.1016/j.leukres.2024.107599

Josefine Krüger , Igor Wolfgang Blau , Olga Blau , Alice Bettelli , Laura Rocchi , Massimo Bocchi , Jan Krönke , Lars Bullinger , Ulrich Keller , Axel Nogai

{"title":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","authors":"Josefine Krüger , Igor Wolfgang Blau , Olga Blau , Alice Bettelli , Laura Rocchi , Massimo Bocchi , Jan Krönke , Lars Bullinger , Ulrich Keller , Axel Nogai","doi":"10.1016/j.leukres.2024.107599","DOIUrl":"10.1016/j.leukres.2024.107599","url":null,"abstract":"<div><div>Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of <em>in vitro</em> drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and <em>in vitro</em> drug response of primary myeloma cells was analyzed. <em>In vitro</em> responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability <em>in vitro</em>. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy <em>in vitro</em>. To further validate these <em>in vitro</em> results against <em>in vivo</em> outcomes, screening a larger cohort is necessary.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107599"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis 体重指数对慢性白血病患者服用博舒替尼安全性的影响：事后汇总数据分析。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-24 DOI: 10.1016/j.leukres.2024.107609

Susanne Isfort, Carlo Gambacorti-Passerini, Tim H. Brümmendorf, B. Douglas Smith, Simon Purcell, Maja Strecker, Huadong Zhao, Luke Kuttschreuter, Jane Apperley

引用次数: 0

Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan Ruxolitinib在现实世界骨髓纤维化患者中的安全性和有效性：台湾一项为期两年的观察性研究。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-23 DOI: 10.1016/j.leukres.2024.107601

Ming-Chung Kuo , Chien-Chin Lin , Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Cih-En Huang, I-Ju Chiang, Hao-Wei Cheng, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang

引用次数: 0

The phylogenetic age paradox of non-coding RNAs 非编码 RNA 的系统发育年龄悖论。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-22 DOI: 10.1016/j.leukres.2024.107600

Martin S. Staege

引用次数: 0

A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure 骨髓细胞白血病 1 (MCL1) 抑制剂 tapotoclax (AMG 176) 对低甲基化药物治疗失败后骨髓增生异常综合征患者的 I 期研究。

IF 2.1 4区医学

Leukemia research Pub Date : 2024-10-22 DOI: 10.1016/j.leukres.2024.107602

Kelly S. Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E. Hammond, Mahesh Swaminathan, Alexandre Bazinet, Jacqueline Kimberley, Kristy Bodden, Heather Schneider, Xiao Qin Dong, Sherry A. Pierce, Xuelin Huang, Elias J. Jabbour, Hagop M. Kantarjian, Guillermo Garcia-Manero

引用次数: 0